Last Updated2026-06-02

Market View

₹4,514.5(▼0.02%)

Reporting PeriodQ4 FY26

PFIZERPfizer Limited Forensic Risk Analysis

Name: Pfizer Limited Structural Risk Analysis
Creator: Flagium AI
License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Pharmaceuticals

Risk ClassStable

Market Cap₹22,577 Cr

Primary DriverBalance Sheet Stress

Flagium AI Risk Score

5 / 100

+5 QoQ

Early Deterioration

Sentinel Insight

Financial profile remains stable for now. Weakness is detected in balance sheet stress. No immediate concerns are visible. Risk is increasing at a faster pace.

6.1th %ile (Sector)Accel: +1 Qtrs

Updated2026-06-02

Market View

₹4,514.5▼0.02%

PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Balance Sheet Stress

+8.8 pts

Earnings Quality

+7.2 pts

Stability Adjustment

-11.0 pts

Final Composite Risk5 / 100

Investment Risk Thesis

Historical Trend

Current risk score has declined from 5 → 5 over 13 quarters.

Expected Direction

⚠ Watch

Primary Deterioration Drivers

Inventory Stress
Relative Growth Weakness
Operating Leverage Stress

What to Watch Next Quarter

Debt growth
Operating cash flow
Inventory turnover

Active Risk Objects (6)

CriticalHigh

Operating Leverage Stress

📊 Earnings QualityAnnualActive for 1 Years

More Detail

Impact Weight10/15

MomentumAccelerating

Last SignalQ4 FY2026

Expenses are consistently growing faster than revenues, creating operational pressure.

"The balance sheet is heavily over-leveraged. Interest payments are consuming most of the profit."

Cash Conversion Deficit

📊 Earnings QualityAnnualActive for 3 Years

More Detail

Impact Weight6/15

MomentumPersistent

Last SignalFY2026

PFIZER: OCF below Net Profit in 2/3 recent years.

"Cash conversion is dangerously low. Operational cash flow is significantly trailing reported PAT."

Inventory Stress

📊 Earnings QualityAnnualActive for 2 Years

More Detail

Impact Weight15/15

MomentumDecaying

Last SignalQ4 FY2025

Inventory growth (9.7%) significantly outpaced revenue growth (2.4%).

"Inventory overhang is clearing. Stock levels are normalizing as sales momentum returns."

Profit Collapse

📊 Earnings QualityQuarterlyActive for 1 Qtrs

More Detail

Impact Weight8/15

MomentumDecaying

Last SignalQ2 FY2024

PFIZER: Net Profit collapsed by 52.1% from FY2023 Q2 to FY2024 Q2.

"Earnings quality is stabilizing. The reliance on non-operational items is receding."

Working Capital Expansion

💧 Liquidity & CoverageAnnualActive for 4 Years

More Detail

Impact Weight10/15

MomentumPersistent

Last SignalQ4 FY2026

Working capital expansion detected: Receivable days increased by -10.5%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Relative Growth Weakness

📊 Earnings QualityAnnualActive for 1 Years

More Detail

Impact Weight12/15

MomentumAccelerating

Last SignalQ1 FY2026

Revenue growth consistently lags behind sector median (12.8%).

"Early signs of earnings quality decay. Profitability is being driven by non-core items."

Risk Trajectory

Loading Chart

Resilience Matrix

Metric	Value	vs Sector	Signal
Volatility (σ)	4.67	7.70	✅ RESILIENT
Sensitivity (ε_s)	1	1.00	✅ RESILIENT
Escalation Prob.	5%	5%	✅ NEUTRAL
Safety Buffer	+61.0	+47.0	✅ RESILIENT

Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart

Share Price

Risk Score (0-100)

Market Performance

₹4,514.5(-0.02%)

1M Divergence-6.43%

1 Week-2.74%

1 Month-4.16%

6 Months-9.73%

1 Year-17.39%

2 Year+1.38%

3 Year+22.57%

Sector Average (1M)+2.27%

Sentinel Forensic Assessment

ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in balance sheet stress remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. Strategic vigilance is advised as structural decay is accelerating.

PFIZER • MARKET STRUCTURE

Stage 4 — Declining

The company is in a defensive phase. Sentiment and fundamentals are deteriorating under persistent downward pressure, indicating elevated risk levels.

Stage Transition Prob.0%

Trend QualityDeteriorating

Phase Progression

Phase Progression Score0%

Readiness LabelLow (Early Base Consolidation)

Probability of Advancing0%

CoinTree Momentum

Composite Z-Score-0.6266σ

Weakening momentum trend

Universe Rank#2238 of 2716

Top 82.40% in momentum strength

Timeframe Sparklines

1W-2.7%

1M-4.2%

6M-9.7%

Weinstein Indicators

150 DMA₹4,885.5

200 DMA₹4,970.4

150 DMA Slope-1.3026%Declining

Relative Strength-3.82%Lagging

Relative Turnover (RTR)0.6756

ParticipationWeak

PEER COMPARISON

Ranked comparison against sector peers

This company appears relatively stable compared to the Sector Mean (19).

Ticker	Risk Score	Sector %ile	Delta	Flags	Accel	Primary Driver
ABBOTINDIAABBOTINDIA	0	0th	0	0	+0	GovernanceStable
PFIZERPfizer Limited	5	6th	+5	6	+1	Balance Sheet StressStable
AARTIDRUGSAarti Drugs Limited	19	51th	-5	11	+0	Competitive PositionStable
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited	23	63th	-5	20	+0	Balance Sheet StressWatch